Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Herpes Simplex Virus Treatment Market
Herpes Simplex Virus Treatment Market size was around USD 2.6 billion in 2022 and is poised to expand at 4% CAGR from 2023 to 2032. Major growth factors for the market are increasing prevalence of herpes infection, rising research and development, growing government funding and awareness, globalization & increased travel, and increasing healthcare expenditure.
The rising prevalence of herpes infection is a significant contributor to the market. For instance, according to the Centers for Disease Control and Prevention (CDC), there were about 572,000 new genital herpes infections in the U.S. alone in 2021. As the prevalence of HSV infections increases, the number of individuals seeking diagnosis and treatment also rises, thus fostering the market expansion.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Herpes Simplex Virus Treatment Market Size in 2022: | USD 2.6 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 4% |
2032 Value Projection: | USD 3.8 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 220 |
Tables, Charts & Figures: | 315 |
Segments covered: | Virus Type, Drug Type, Site, Route of Administration, Distribution Channel & Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Herpes simplex virus (HSV) treatment refers to the medical interventions and therapeutic approaches aimed at managing and controlling infections caused by the herpes simplex virus. The treatment primarily focuses on alleviating symptoms, reducing the frequency and severity of outbreaks, and preventing the transmission of the virus to others. Antiviral drugs including acyclovir, valacyclovir, and famciclovir are commonly prescribed. They work by inhibiting the replication of the virus, reducing the severity of symptoms, and suppressing recurrent outbreaks.